{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:59:42Z","timestamp":1777946382198,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Central nervous system (CNS) metastases from Wilms tumor (WT) are exceedingly rare. Intracerebral hemorrhage secondary to metastatic WT is even less common, and the management of such cases is further complicated when patients are receiving a direct oral anticoagulant (DOAC) like Rivaroxaban, for which pediatric reversal guidelines are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report on the case of a 5-year-old boy with relapsed stage IV Wilms tumor who presented with rapidly progressive neurological deterioration caused by brain metastases with extensive intraparenchymal and intraventricular hemorrhage while receiving Rivaroxaban due to prior thrombosis. An emergent craniotomy and tumor resection was safely performed after emergent reversal of anticoagulation with Rivaroxaban using Andexanet alfa, administered in this pediatric patient with off-label consent in the setting of a life-threatening intracranial hemorrhage requiring emergent neurosurgical intervention. No excessive intraoperative bleeding was noted. Treatment for relapsed WT according to the SIOP-UMBRELLA-Protocol was initiated. Three weeks after Andexanet alfa treatment, a thrombotic event in the left iliac veins occurred, requiring anticoagulation with unfractionated heparin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights the therapeutic challenges of managing intracranial hemorrhage in a pediatric patient requiring emergent neurosurgical debulking in the setting of Rivaroxaban anticoagulation. To our knowledge, this is the second case reporting on Rivaroxaban reversal through Andexanet alfa in children. Early multidisciplinary intervention, meticulous neurosurgical management and continuation of oncologic therapy can lead to favorable outcomes even in such complex presentations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00381-026-07286-w","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:03:29Z","timestamp":1777741409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emergency reversal of Rivaroxaban with Andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor"],"prefix":"10.1007","volume":"42","author":[{"given":"Artem","family":"Rafaelian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae-Yeon","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Armbrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Gessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Spang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almut","family":"Meyer-Bahlburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hingst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl Friedrich","family":"Classen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Dubinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa Marta","family":"Cardesa-Salzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"7286_CR1","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.ejca.2006.05.010","volume":"42","author":"G Pastore","year":"2006","unstructured":"Pastore G, Znaor A, Spreafico F et al (2006) Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42:2103\u20132114. https:\/\/doi.org\/10.1016\/j.ejca.2006.05.010","journal-title":"Eur J Cancer"},{"key":"7286_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mpo.2950210305","volume":"21","author":"N Breslow","year":"1993","unstructured":"Breslow N, Olshan A, Beckwith JB, Green DM (1993) Epidemiology of Wilms tumor. Med Pediatr Oncol 21:172\u2013181. https:\/\/doi.org\/10.1002\/mpo.2950210305","journal-title":"Med Pediatr Oncol"},{"key":"7286_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/jmg.2006.041723","volume":"43","author":"RH Scott","year":"2006","unstructured":"Scott RH, Stiller CA, Walker L, Rahman N (2006) Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 43:705\u2013715","journal-title":"J Med Genet"},{"key":"7286_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3744","author":"DM Green","year":"1998","unstructured":"Green DM et al (1998) Effect of duration of treatment on treatment outcome and cost of treatment for Wilms\u2019 tumor: a report from the National Wilms\u2019 Tumor Study Group. Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.1998.16.12.3744","journal-title":"Clin Oncol"},{"key":"7286_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27430","author":"DSM Iaboni","year":"2019","unstructured":"Iaboni DSM, Chi YY, Kim Y et al (2019) Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.27430","journal-title":"Pediatr Blood Cancer"},{"key":"7286_CR6","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1182\/bloodadvances.2020003244","volume":"4","author":"P Connor","year":"2020","unstructured":"Connor P, van Kammen MS, Lensing AWA et al (2020) Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT). Blood Adv 4:6250\u20136258. https:\/\/doi.org\/10.1182\/bloodadvances.2020003244","journal-title":"Blood Adv"},{"key":"7286_CR7","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1182\/bloodadvances.2022008160","volume":"6","author":"JS Palumbo","year":"2022","unstructured":"Palumbo JS, Lensing AWA, Brand\u00e3o LR et al (2022) Anticoagulation in pediatric cancer\u2013associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv 6:5821\u20135828. https:\/\/doi.org\/10.1182\/bloodadvances.2022008160","journal-title":"Blood Adv"},{"key":"7286_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2110236","author":"M Daei","year":"2022","unstructured":"Daei M, Abbasi G, Khalili H, Heidari Z (2022) Direct oral anticoagulants toxicity in children: an overview and practical guide. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2022.2110236","journal-title":"Expert Opin Drug Saf"},{"key":"7286_CR9","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/nejmoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet Alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 373:2413\u20132424. https:\/\/doi.org\/10.1056\/nejmoa1510991","journal-title":"N Engl J Med"},{"key":"7286_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-025-02393-z","author":"HF Hounchonou","year":"2025","unstructured":"Hounchonou HF, Albrecht C, Jelinek J et al (2025) Andexanet Alfa in emergency cranial neurosurgical procedures: a bicentric analysis of efficacy and safety. Neurocrit Care. https:\/\/doi.org\/10.1007\/s12028-025-02393-z","journal-title":"Neurocrit Care"},{"key":"7286_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29484","author":"K Takasaki","year":"2022","unstructured":"Takasaki K, Hehir D, Raffini L et al (2022) Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.29484","journal-title":"Pediatr Blood Cancer"},{"key":"7286_CR12","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.3345\/kjp.2016.59.11.S96","volume":"59","author":"A Akak\u0131n","year":"2016","unstructured":"Akak\u0131n A, Y\u0131lmaz B, Ek\u015fi M\u015e et al (2016) Relapsed Wilms\u2019 tumor with multiple brain metastasis. Korean J Pediatr 59:S96\u2013S98. https:\/\/doi.org\/10.3345\/kjp.2016.59.11.S96","journal-title":"Korean J Pediatr"},{"key":"7286_CR13","doi-asserted-by":"crossref","unstructured":"Macrae R, Grimard L, Hsu E, et al (2002) Brain metastases in Wilms Tumor: case report and literature review","DOI":"10.1097\/00043426-200202000-00019"},{"key":"7286_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/pbc.20150","volume":"43","author":"MM Van Den Heuvel-Eibrink","year":"2004","unstructured":"Van Den Heuvel-Eibrink MM, Graf N, Pein F et al (2004) Intracranial relapse in Wilms tumor patients. Pediatr Blood Cancer 43:737\u2013741. https:\/\/doi.org\/10.1002\/pbc.20150","journal-title":"Pediatr Blood Cancer"},{"key":"7286_CR15","doi-asserted-by":"publisher","unstructured":"Venkatramani R, Chi YY, Coppes MJ, et al (2017) Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. Pediatr Blood Cancer 64:. https:\/\/doi.org\/10.1002\/pbc.26406","DOI":"10.1002\/pbc.26406"},{"key":"7286_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-022-05502-x","author":"PJ Madsen","year":"2022","unstructured":"Madsen PJ et al (2022) Surgical management and outcomes of intracranial metastatic Wilms\u2019 tumor in the pediatric population: a case series. Childs Nerv Syst. https:\/\/doi.org\/10.1007\/s00381-022-05502-x","journal-title":"Childs Nerv Syst"},{"key":"7286_CR17","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS et al (2020) Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology 7:e18\u2013e27. https:\/\/doi.org\/10.1016\/S2352-3026(19)30219-4","journal-title":"The Lancet Haematology"},{"key":"7286_CR18","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3026(25)00067-5","volume":"12","author":"C Male","year":"2025","unstructured":"Male C, Lensing AWA, Chan AKC et al (2025) Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial. Lancet Haematol 12:e357\u2013e364. https:\/\/doi.org\/10.1016\/S2352-3026(25)00067-5","journal-title":"Lancet Haematol"},{"key":"7286_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-018-0186-0","author":"D Kubitza","year":"2018","unstructured":"Kubitza D et al (2018) Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. https:\/\/doi.org\/10.1186\/s12959-018-0186-0","journal-title":"Thromb J"},{"key":"7286_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2019000885","volume":"4","author":"G Lu","year":"2020","unstructured":"Lu G, Conley PB, Leeds JM et al (2020) A phase 2 PK\/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv 4:728\u2013739. https:\/\/doi.org\/10.1182\/bloodadvances.2019000885","journal-title":"Blood Adv"},{"key":"7286_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.25475","volume":"94","author":"A Cuker","year":"2019","unstructured":"Cuker A, Burnett A, Triller D et al (2019) Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. Am J Hematol 94:697\u2013709","journal-title":"Am J Hematol"},{"key":"7286_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/nejmoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW et al (2019) Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380:1326\u20131335. https:\/\/doi.org\/10.1056\/nejmoa1814051","journal-title":"N Engl J Med"},{"key":"7286_CR23","doi-asserted-by":"crossref","unstructured":"Levy JH, Douketis J, Steiner T et al (2018) Prothrombin complex concentrates for perioperative Vitamin K antagonist and non-Vitamin K anticoagulant reversal. Anesthesiology 129:1171\u20131184","DOI":"10.1097\/ALN.0000000000002399"},{"key":"7286_CR24","doi-asserted-by":"publisher","unstructured":"Jaspers T, Shudofsky K, Huisman MV et al (2021) A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor\u2013related major bleeding. Res Pract Thromb Haemost. https:\/\/doi.org\/10.1002\/rth2.12518","DOI":"10.1002\/rth2.12518"},{"key":"7286_CR25","doi-asserted-by":"publisher","unstructured":"Moia M, Squizzato A\u00a0(2019) Reversal agents for oral anticoagulant-associated major or life-threatening bleeding Internal and Emergency Medicine 14(8) 1233-1239. https:\/\/doi.org\/10.1007\/s11739-019-02177-2","DOI":"10.1007\/s11739-019-02177-2"},{"key":"7286_CR26","doi-asserted-by":"publisher","unstructured":"Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Sch\u00fcnemann HJ, Nieuwlaat R (2019) Management of direct factor Xa inhibitor\u2013related major bleeding with prothrombin complex concentrate: a meta-analysis. Abstract Blood Advances 3(2) 158-167. https:\/\/doi.org\/10.1182\/bloodadvances.2018024133","DOI":"10.1182\/bloodadvances.2018024133"},{"key":"7286_CR27","doi-asserted-by":"publisher","unstructured":"\u00a0Daei M, Abbasi G, Khalili H, Heidari Z (2022)\u00a0Direct oral anticoagulants toxicity in children: an overview and practical guide. Expert Opinion on Drug Safety 21(9), 1183-1192. https:\/\/doi.org\/10.1080\/14740338.2022.2110236","DOI":"10.1080\/14740338.2022.2110236"},{"key":"7286_CR28","doi-asserted-by":"publisher","unstructured":"Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI (2022)\u00a0Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Abstract Critical Care 26(1). https:\/\/doi.org\/10.1186\/s13054-022-04043-8","DOI":"10.1186\/s13054-022-04043-8"},{"key":"7286_CR29","doi-asserted-by":"publisher","unstructured":"Jakowenko N, Nguyen S, Ruegger M et al (2020) Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res 196:276\u2013282.\nhttps:\/\/doi.org\/10.1016\/j.thromres.2020.09.002","DOI":"10.1016\/j.thromres.2020.09.002"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-026-07286-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07286-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:03:30Z","timestamp":1777741410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-026-07286-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7286"],"URL":"https:\/\/doi.org\/10.1007\/s00381-026-07286-w","relation":{},"ISSN":["1433-0350"],"issn-type":[{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}